Beschreibung

As an experienced C-level executive, I offer a unique blend of strategic leadership and deep scientific expertise. In my previous roles as Chief Scientific Officer, I have:

Strategic Leadership

Defined and executed internal R&D strategies
Built comprehensive business plans
Supported successful fundraising efforts

Scientific Expertise

Extensive experience in drug discovery, from early ideation to translational and preclinical development, and clinical proof-of-concept (PoC)
Leveraged personal expertise and team skills to drive decisions on early project selection and progression through to clinical PoC
Established and maintained internal and external partnerships to advance scientific ideas collaboratively

This combination of strategic acumen and scientific depth makes me an ideal interim management or consulting partner for organizations seeking to accelerate their drug discovery and development programs. I am adept at quickly assessing the landscape, identifying key opportunities, and driving cross-functional teams to deliver tangible results.

Whether you need support with R&D strategy, business planning, fundraising, or hands-on scientific leadership, I am well-equipped to provide the expertise and guidance to help your organization achieve its goals.

Branchenexpertise

Sprachen

Englisch
Muttersprachlich oder zweisprachig
Deutsch
Grundkenntnisse

Arbeitsortpräferenzen

Vor Ort möglich

Munich (bis zu 50 km), Augsburg (bis zu 50 km)

Confidential
Chief Technology Officer - Fractional
BIOTECHNOLOGIE
Juli 2024 - Heute (1 Jahr und 11 Monate)
Cambridge, Vereinigtes Königreich
Start-up in oncology. Manage preclinical CROs and CDMOs to design and deliver research and clinical grade mRNA cancer vaccine drug product. Work with CSO to generate data to support patent and regulatory filings, and fund-raising. Fractional role.
mRNA Vaccines Drug discovery Oncology Start-up
Various
Freelance Consultant
BIOTECHNOLOGIE
November 2020 - Heute (5 Jahre und 7 Monate)
Munich, Deutschland
Consultant via companies such as Third Bridge, Atheneum, Guidepoint and VisasQ. Advised primarily on mRNA therapeutics (manufacture, potential, investment opportunities). Also advised on live biotherapeutic products (microbiome-based drugs).
Due diligence Drug Discovery Drug development Start-up Strategy
Ethris
Senior Vice President - Discovery Biology
BIOTECHNOLOGIE
Januar 2024 - Juli 2024 (6 Monate)
Planegg, BY, Germany
Pipeline expansion, indication evaluation, mRNA therapies, pulmonary disease, rare disease. Also lead bioanalytics team.
Drug Discovery mRNA Drug Development Bioanalytics Rare diseases